Lipid metabolism and coagulation of two contraceptives: Correlation to serum concentrations of levonorgestrel and gestodene

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Lipid metabolism and coagulation of two contraceptives : Correlation to serum concentrations of levonorgestrel and gestodene. / Kjær, A.; Lebech, A. M.; Borggaard, B.; Refn, H.; Pedersen, L. R.; Schierup, L.; Bremmelgaard, A.

In: Contraception, Vol. 40, No. 6, 12.1989, p. 665-673.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kjær, A, Lebech, AM, Borggaard, B, Refn, H, Pedersen, LR, Schierup, L & Bremmelgaard, A 1989, 'Lipid metabolism and coagulation of two contraceptives: Correlation to serum concentrations of levonorgestrel and gestodene', Contraception, vol. 40, no. 6, pp. 665-673. https://doi.org/10.1016/0010-7824(89)90070-X

APA

Kjær, A., Lebech, A. M., Borggaard, B., Refn, H., Pedersen, L. R., Schierup, L., & Bremmelgaard, A. (1989). Lipid metabolism and coagulation of two contraceptives: Correlation to serum concentrations of levonorgestrel and gestodene. Contraception, 40(6), 665-673. https://doi.org/10.1016/0010-7824(89)90070-X

Vancouver

Kjær A, Lebech AM, Borggaard B, Refn H, Pedersen LR, Schierup L et al. Lipid metabolism and coagulation of two contraceptives: Correlation to serum concentrations of levonorgestrel and gestodene. Contraception. 1989 Dec;40(6):665-673. https://doi.org/10.1016/0010-7824(89)90070-X

Author

Kjær, A. ; Lebech, A. M. ; Borggaard, B. ; Refn, H. ; Pedersen, L. R. ; Schierup, L. ; Bremmelgaard, A. / Lipid metabolism and coagulation of two contraceptives : Correlation to serum concentrations of levonorgestrel and gestodene. In: Contraception. 1989 ; Vol. 40, No. 6. pp. 665-673.

Bibtex

@article{149be5a76c5745aead92d162f7953b95,
title = "Lipid metabolism and coagulation of two contraceptives: Correlation to serum concentrations of levonorgestrel and gestodene",
abstract = "The effects of two triphasic oral contraceptives containing the same amount of ethinylestradiol (EE) in combination with levonorgestrel (LNG) or gestodene (GES), respectively, on lipid metabolism and coagulation were studied. Serum concentrations of GES and LNG were determined at the same time. Thirty-three healthy women were randomized into two groups receiving either of the preparations. Before treatment and in the 3rd and the 6th cycle, blood samples were drawn in the morning while subjects were still in bed to obtain basal conditions. HDL2-cholesterol decreased in the LNG group but was unchanged in the GES group, whereas apolipoprotein Al increased in the GES but not in the LNG group. Antithrombin III decreased in the GES group but was unchanged in the LNG- treated women. Factor VII increased in both groups, but more in the GES group. It is concluded that GES has a positive influence on lipid metabolism, and has a slightly negative influence on coagulation but the latter is more likely to be without clinical relevance. The positive influence of GES compared to LNG on lipids is probably due to its lower androgenicity and not to differences in bioavailability.",
author = "A. Kj{\ae}r and Lebech, {A. M.} and B. Borggaard and H. Refn and Pedersen, {L. R.} and L. Schierup and A. Bremmelgaard",
year = "1989",
month = dec,
doi = "10.1016/0010-7824(89)90070-X",
language = "English",
volume = "40",
pages = "665--673",
journal = "Contraception",
issn = "0010-7824",
publisher = "Elsevier",
number = "6",

}

RIS

TY - JOUR

T1 - Lipid metabolism and coagulation of two contraceptives

T2 - Correlation to serum concentrations of levonorgestrel and gestodene

AU - Kjær, A.

AU - Lebech, A. M.

AU - Borggaard, B.

AU - Refn, H.

AU - Pedersen, L. R.

AU - Schierup, L.

AU - Bremmelgaard, A.

PY - 1989/12

Y1 - 1989/12

N2 - The effects of two triphasic oral contraceptives containing the same amount of ethinylestradiol (EE) in combination with levonorgestrel (LNG) or gestodene (GES), respectively, on lipid metabolism and coagulation were studied. Serum concentrations of GES and LNG were determined at the same time. Thirty-three healthy women were randomized into two groups receiving either of the preparations. Before treatment and in the 3rd and the 6th cycle, blood samples were drawn in the morning while subjects were still in bed to obtain basal conditions. HDL2-cholesterol decreased in the LNG group but was unchanged in the GES group, whereas apolipoprotein Al increased in the GES but not in the LNG group. Antithrombin III decreased in the GES group but was unchanged in the LNG- treated women. Factor VII increased in both groups, but more in the GES group. It is concluded that GES has a positive influence on lipid metabolism, and has a slightly negative influence on coagulation but the latter is more likely to be without clinical relevance. The positive influence of GES compared to LNG on lipids is probably due to its lower androgenicity and not to differences in bioavailability.

AB - The effects of two triphasic oral contraceptives containing the same amount of ethinylestradiol (EE) in combination with levonorgestrel (LNG) or gestodene (GES), respectively, on lipid metabolism and coagulation were studied. Serum concentrations of GES and LNG were determined at the same time. Thirty-three healthy women were randomized into two groups receiving either of the preparations. Before treatment and in the 3rd and the 6th cycle, blood samples were drawn in the morning while subjects were still in bed to obtain basal conditions. HDL2-cholesterol decreased in the LNG group but was unchanged in the GES group, whereas apolipoprotein Al increased in the GES but not in the LNG group. Antithrombin III decreased in the GES group but was unchanged in the LNG- treated women. Factor VII increased in both groups, but more in the GES group. It is concluded that GES has a positive influence on lipid metabolism, and has a slightly negative influence on coagulation but the latter is more likely to be without clinical relevance. The positive influence of GES compared to LNG on lipids is probably due to its lower androgenicity and not to differences in bioavailability.

UR - http://www.scopus.com/inward/record.url?scp=0024801657&partnerID=8YFLogxK

U2 - 10.1016/0010-7824(89)90070-X

DO - 10.1016/0010-7824(89)90070-X

M3 - Journal article

C2 - 2515940

AN - SCOPUS:0024801657

VL - 40

SP - 665

EP - 673

JO - Contraception

JF - Contraception

SN - 0010-7824

IS - 6

ER -

ID: 283517799